94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1562766
This article is part of the Research Topic Research on Nanomaterials in Tumor Diagnosis and Therapy, Volume II View all 4 articles
Nanomaterials for targeted drug delivery for immunotherapy of digestive tract tumors
Provisionally accepted
Mingzhu Li 1
Ningxin Li 2
Haozhe Piao 1*
Shengbo Jin 3 Hongzhe Wei 2 Qian Liu 3 Jun Yu 3 Wenping Wang 1 Siyao Ma 1
Yuxin Jiang 3
Huini Yao 2 Yue Shen 3 Jiaqing Fu 3- 1 Liaoning Cancer Hospital, China Medical University, Shenyang, China
- 2 China Medical University, Shenyang, Liaoning Province, China
- 3 Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China
The incidence and mortality rates of digestive tract tumors, especially gastric and colorectal cancers, are high worldwide. Owing to their unique advantages, such as efficient drug loading, safety, and targeting properties, nanoparticles (NPs) have demonstrated great potential in the treatment of gastrointestinal tumors. However, their practical application is limited by several factors, such as high costs, few clinical trials, and long approval periods. In this review, we summarize three types of immunotherapeutic nanomaterial drugs for gastrointestinal tumors: organic, inorganic, and hybrid nanomaterials. This article also discusses the current status of research and development in this field and the advantages of each type of material to provide theoretical references for developing new drugs and advancing clinical research.
Keywords: nanomaterials, Immunotherapy, Digestive tract tumors, Drug delivery, application
Received: 22 Jan 2025; Accepted: 20 Feb 2025.
Copyright: © 2025 Li, Li, Piao, Jin, Wei, Liu, Yu, Wang, Ma, Jiang, Yao, Shen and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Haozhe Piao, Liaoning Cancer Hospital, China Medical University, Shenyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.